$1.28
At close: Apr 25, 4:32 PM EDT
$1.28
0.000.00%
Pre-Market: Apr 25, 4:32 PM EDT
Comments
Loading...
Fate Therapeutics Analyst Ratings and Price Targets | NASDAQ:FATE | Benzinga
Fate Therapeutics Inc has a consensus price target of $7.89 based on the ratings of 23 analysts. The high is $28 issued by Baird on June 3, 2022. The low is $3 issued by Stifel on March 6, 2025. The 3 most-recent analyst ratings were released by Stifel, Wedbush, and Wells Fargo on March 6, 2025, respectively. With an average price target of $4 between Stifel, Wedbush, and Wells Fargo, there's an implied 212.50% upside for Fate Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Wedbush
Wells Fargo
HC Wainwright & Co.
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Fate Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/06/2025 | Buy Now | 134.38% | Stifel | Benjamin Burnett46% | $5 → $3 | Maintains | Hold | Get Alert |
| 03/06/2025 | Buy Now | 290.62% | Wedbush | David Nierengarten63% | $5 → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 03/06/2025 | Buy Now | 212.5% | Wells Fargo | Yanan Zhu36% | $5 → $4 | Maintains | Equal-Weight | Get Alert |
| 03/06/2025 | Buy Now | — | Needham | Gil Blum51% | — | Reiterates | Hold → Hold | Get Alert |
| 11/19/2024 | Buy Now | — | Needham | Gil Blum51% | — | Reiterates | → Hold | Get Alert |
| 11/13/2024 | Buy Now | — | Needham | Gil Blum51% | — | Reiterates | → Hold | Get Alert |
| 08/22/2024 | Buy Now | 290.62% | HC Wainwright & Co. | Raghuram Selvaraju42% | $5 → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 08/14/2024 | Buy Now | — | Needham | Gil Blum51% | — | Reiterates | → Hold | Get Alert |
| 06/17/2024 | Buy Now | 368.75% | Piper Sandler | Edward Tenthoff52% | $4 → $6 | Upgrade | Neutral → Overweight | Get Alert |
| 05/16/2024 | Buy Now | 290.62% | HC Wainwright & Co. | Raghuram Selvaraju42% | $7 → $5 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | 603.13% | Canaccord Genuity | Bill Maughan19% | $11 → $9 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 368.75% | BMO Capital | Etzer Darout49% | $7 → $6 | Maintains | Market Perform | Get Alert |
| 05/10/2024 | Buy Now | 290.62% | Wedbush | David Nierengarten63% | $7 → $5 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | 212.5% | Piper Sandler | Edward Tenthoff52% | $7 → $4 | Maintains | Neutral | Get Alert |
| 05/06/2024 | Buy Now | 446.88% | Wedbush | David Nierengarten63% | $7 → $7 | Reiterates | Neutral → Neutral | Get Alert |
| 04/23/2024 | Buy Now | 446.88% | Wedbush | David Nierengarten63% | $7 → $7 | Reiterates | Neutral → Neutral | Get Alert |
| 04/11/2024 | Buy Now | — | Needham | Gil Blum51% | — | Reiterates | → Hold | Get Alert |
| 03/28/2024 | Buy Now | 368.75% | B of A Securities | Tazeen Ahmad55% | $2 → $6 | Maintains | Underperform | Get Alert |
| 03/19/2024 | Buy Now | 446.88% | HC Wainwright & Co. | Raghuram Selvaraju42% | $7 → $7 | Reiterates | Neutral → Neutral | Get Alert |
| 02/27/2024 | Buy Now | 446.88% | Morgan Stanley | Michael Ulz61% | $3 → $7 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | Buy Now | 446.88% | BMO Capital | Etzer Darout49% | $6 → $7 | Maintains | Market Perform | Get Alert |
| 02/27/2024 | Buy Now | 681.25% | Barclays | Peter Lawson42% | $6 → $10 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | 446.88% | Wedbush | David Nierengarten63% | $3 → $7 | Maintains | Neutral | Get Alert |
| 02/27/2024 | Buy Now | — | Oppenheimer | Matthew Biegler37% | — | Reiterates | Perform → Perform | Get Alert |
| 11/20/2023 | Buy Now | 525% | Mizuho | Mara Goldstein57% | $12 → $8 | Maintains | Buy | Get Alert |
| 11/13/2023 | Buy Now | 134.38% | Morgan Stanley | Michael Ulz61% | $5 → $3 | Maintains | Equal-Weight | Get Alert |
| 11/09/2023 | Buy Now | 368.75% | BMO Capital | Etzer Darout49% | $5.4 → $6 | Maintains | Market Perform | Get Alert |
| 11/09/2023 | Buy Now | 134.38% | Wedbush | David Nierengarten63% | $6 → $3 | Maintains | Neutral | Get Alert |
| 11/09/2023 | Buy Now | 290.62% | Wells Fargo | Yanan Zhu36% | $6 → $5 | Maintains | Equal-Weight | Get Alert |
| 09/07/2023 | Buy Now | 290.62% | Cantor Fitzgerald | Li Watsek40% | → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 08/16/2023 | Buy Now | 446.88% | Truist Securities | Robyn Karnauskas55% | → $7 | Reiterates | Hold → Hold | Get Alert |
| 08/10/2023 | Buy Now | 290.62% | Morgan Stanley | Michael Ulz61% | $8 → $5 | Maintains | Equal-Weight | Get Alert |
| 08/10/2023 | Buy Now | 368.75% | Barclays | Peter Lawson42% | $12 → $6 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 321.88% | BMO Capital | Etzer Darout49% | $6 → $5.4 | Maintains | Market Perform | Get Alert |
| 08/09/2023 | Buy Now | 681.25% | EF Hutton | Tony Butler43% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | 446.88% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $7 | Reiterates | → Neutral | Get Alert |
| 05/04/2023 | Buy Now | 290.62% | Stifel | Benjamin Burnett46% | $5.3 → $5 | Maintains | Hold | Get Alert |
| 05/04/2023 | Buy Now | 290.62% | Cantor Fitzgerald | Li Watsek40% | $8 → $5 | Maintains | Neutral | Get Alert |
| 03/27/2023 | Buy Now | 368.75% | Wells Fargo | Yanan Zhu36% | → $6 | Assumes | → Equal-Weight | Get Alert |
| 03/02/2023 | Buy Now | 681.25% | Citigroup | Yigal Nochomovitz56% | $9 → $10 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | 681.25% | EF Hutton | Tony Butler43% | → $10 | Reiterates | → Buy | Get Alert |
| 01/24/2023 | Buy Now | 446.88% | HC Wainwright & Co. | Robert Burns43% | $115 → $7 | Downgrade | Buy → Neutral | Get Alert |
| 01/09/2023 | Buy Now | 212.5% | Goldman Sachs | Andrea Tan40% | $10 → $4 | Maintains | Sell | Get Alert |
| 01/06/2023 | Buy Now | 525% | Morgan Stanley | Michael Ulz61% | $35 → $8 | Maintains | Equal-Weight | Get Alert |
| 01/06/2023 | Buy Now | 212.5% | B of A Securities | Tazeen Ahmad55% | $72 → $4 | Downgrade | Buy → Underperform | Get Alert |
| 01/06/2023 | Buy Now | 314.06% | Stifel | Benjamin Burnett46% | $107 → $5.3 | Downgrade | Buy → Hold | Get Alert |
| 01/06/2023 | Buy Now | 681.25% | EF Hutton | Tony Butler43% | $16 → $10 | Maintains | Buy | Get Alert |
| 01/06/2023 | Buy Now | 446.88% | Wedbush | David Nierengarten63% | → $7 | Downgrade | Outperform → Neutral | Get Alert |
| 01/06/2023 | Buy Now | 681.25% | SVB Leerink | Daina Graybosch43% | $62 → $10 | Maintains | Outperform | Get Alert |
| 01/06/2023 | Buy Now | — | Cowen & Co. | Tyler Van Buren44% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 01/06/2023 | Buy Now | 837.5% | Piper Sandler | Edward Tenthoff52% | $71 → $12 | Downgrade | Overweight → Neutral | Get Alert |
| 01/06/2023 | Buy Now | 446.88% | BMO Capital | Etzer Darout49% | $20 → $7 | Downgrade | Outperform → Market Perform | Get Alert |
| 01/06/2023 | Buy Now | 446.88% | Truist Securities | Robyn Karnauskas55% | $46 → $7 | Downgrade | Buy → Hold | Get Alert |
| 01/05/2023 | Buy Now | 1150% | EF Hutton | Tony Butler43% | → $16 | Initiates | → Buy | Get Alert |
| 01/03/2023 | Buy Now | — | Guggenheim | Michael Schmitz42% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/22/2022 | Buy Now | — | Oppenheimer | Matthew Biegler37% | — | Downgrade | Outperform → Perform | Get Alert |
| 12/15/2022 | Buy Now | 681.25% | Goldman Sachs | Andrea Tan40% | → $10 | Initiates | → Sell | Get Alert |
| 12/13/2022 | Buy Now | 3493.75% | Truist Securities | Robyn Karnauskas55% | $51 → $46 | Maintains | Buy | Get Alert |
| 12/13/2022 | Buy Now | 4743.75% | SVB Leerink | Daina Graybosch43% | $64 → $62 | Maintains | Outperform | Get Alert |
| 11/16/2022 | Buy Now | 6150% | Citigroup | Yigal Nochomovitz56% | $87 → $80 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 3415.63% | Cantor Fitzgerald | Li Watsek40% | $98 → $45 | Assumes | → Overweight | Get Alert |
| 09/09/2022 | Buy Now | 2634.38% | Morgan Stanley | Michael Ulz61% | $45 → $35 | Maintains | Equal-Weight | Get Alert |
| 07/28/2022 | Buy Now | — | Needham | Gil Blum51% | — | Initiates | → Hold | Get Alert |
| 07/12/2022 | Buy Now | 3571.88% | BMO Capital | Etzer Darout49% | $50 → $47 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/11/2022 | Buy Now | 3571.88% | BMO Capital | Etzer Darout49% | → $47 | Upgrade | Market Perform → Outperform | Get Alert |
| 06/03/2022 | Buy Now | 2087.5% | Baird | Jack Allen 36% | → $28 | Initiates | → Neutral | Get Alert |
| 05/23/2022 | Buy Now | 5446.88% | Piper Sandler | Edward Tenthoff52% | $113 → $71 | Maintains | Overweight | Get Alert |
| 05/05/2022 | Buy Now | 3415.63% | Morgan Stanley | Michael Ulz61% | $52 → $45 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Fate Therapeutics (FATE) stock?
The latest price target for Fate Therapeutics (NASDAQ:FATE) was reported by Stifel on March 6, 2025. The analyst firm set a price target for $3.00 expecting FATE to rise to within 12 months (a possible 134.38% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Fate Therapeutics (FATE)?
The latest analyst rating for Fate Therapeutics (NASDAQ:FATE) was provided by Stifel, and Fate Therapeutics maintained their hold rating.
When was the last upgrade for Fate Therapeutics (FATE)?
The last upgrade for Fate Therapeutics Inc happened on June 17, 2024 when Piper Sandler raised their price target to $6. Piper Sandler previously had a neutral for Fate Therapeutics Inc.
When was the last downgrade for Fate Therapeutics (FATE)?
The last downgrade for Fate Therapeutics Inc happened on January 24, 2023 when HC Wainwright & Co. changed their price target from $115 to $7 for Fate Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Fate Therapeutics (FATE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fate Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fate Therapeutics was filed on March 6, 2025 so you should expect the next rating to be made available sometime around March 6, 2026.
Is the Analyst Rating Fate Therapeutics (FATE) correct?
While ratings are subjective and will change, the latest Fate Therapeutics (FATE) rating was a maintained with a price target of $5.00 to $3.00. The current price Fate Therapeutics (FATE) is trading at is $1.28, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
